TY - JOUR
T1 - Child mortality according to maternal and infant HIV status in Zimbabwe
AU - Marinda, Edmore
AU - Humphrey, Jean
AU - Iliff, Peter J.
AU - Mutasa, Kuda
AU - Nathoo, Kusum J.
AU - Piwoz, Ellen G.
AU - Moulton, Lawrence Hale
AU - Salama, Peter
AU - Ward, Brian J.
AU - Chidawanyika, Henry
AU - Hargrove, John
AU - Mahomva, Agnes
AU - Majo, Florence
AU - Malaba, Lucie
AU - Mbizvo, Michael
AU - Mzengeza, Faith
AU - Nathoo, Kusum
AU - Ndhlovu, Mary
AU - Ntozini, Robert
AU - Propper, Maria Lidia de Moura
AU - Rambanepasi, Philipa
AU - Ruff, Andrea
AU - Tavengwa, Naume
AU - Zijenah, Lynn
AU - Zunguza, Claire
AU - Zvandasara, Partson
PY - 2007/6
Y1 - 2007/6
N2 - BACKGROUND: HIV causes substantial mortality among African children but there is limited data on how this is influenced by maternal or infant infection status and timing. METHODS: Children enrolled in the ZVITAMBO trial were divided into 5 groups: those born to HIV-negative mothers (NE, n = 9510), those born to HIV-positive mothers but noninfected (NI, n = 3135), those infected in utero (IU, n = 381), those infected intrapartum (IP, n = 508), and those infected postnatally (PN, n = 258). Their mortality was estimated. RESULTS: Two-year mortality was 2.9% (NE infants), 9.2% (NI), 67.5% (IU), 65.1% (IP), and 33.2% (PN). Between 8 weeks and 6 months, mortality in IU infants quintupled (from 309 to 1686/1000 c-y). The median time from infection to death was 208, 380, and >500 days for IU, IP, and PN infants, respectively. Among NI children, advanced maternal disease was predictive of mortality. Acute respiratory infection was the major cause of death. CONCLUSIONS: Perinatally infected infants are at particular risk of death between 2 and 6 months: cotrimoxazole prophylaxis and early pediatric HAART should be scaled up. Uninfected infants of infected mothers have at least twice the mortality risk of infants born to uninfected mothers: all HIV-exposed infants should be targeted with child survival interventions. HIV-positive mothers with more advanced disease are not only more likely to infect their infants, but their infants are more likely to die, whether infected or not: provision of antiretroviral treatment to pregnant and lactating women is an urgent need for both mothers and their children.
AB - BACKGROUND: HIV causes substantial mortality among African children but there is limited data on how this is influenced by maternal or infant infection status and timing. METHODS: Children enrolled in the ZVITAMBO trial were divided into 5 groups: those born to HIV-negative mothers (NE, n = 9510), those born to HIV-positive mothers but noninfected (NI, n = 3135), those infected in utero (IU, n = 381), those infected intrapartum (IP, n = 508), and those infected postnatally (PN, n = 258). Their mortality was estimated. RESULTS: Two-year mortality was 2.9% (NE infants), 9.2% (NI), 67.5% (IU), 65.1% (IP), and 33.2% (PN). Between 8 weeks and 6 months, mortality in IU infants quintupled (from 309 to 1686/1000 c-y). The median time from infection to death was 208, 380, and >500 days for IU, IP, and PN infants, respectively. Among NI children, advanced maternal disease was predictive of mortality. Acute respiratory infection was the major cause of death. CONCLUSIONS: Perinatally infected infants are at particular risk of death between 2 and 6 months: cotrimoxazole prophylaxis and early pediatric HAART should be scaled up. Uninfected infants of infected mothers have at least twice the mortality risk of infants born to uninfected mothers: all HIV-exposed infants should be targeted with child survival interventions. HIV-positive mothers with more advanced disease are not only more likely to infect their infants, but their infants are more likely to die, whether infected or not: provision of antiretroviral treatment to pregnant and lactating women is an urgent need for both mothers and their children.
KW - Child mortality
KW - HIV
KW - Maternal HIV status
KW - Time of infection
UR - http://www.scopus.com/inward/record.url?scp=34249815211&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249815211&partnerID=8YFLogxK
U2 - 10.1097/01.inf.0000264527.69954.4c
DO - 10.1097/01.inf.0000264527.69954.4c
M3 - Article
C2 - 17529870
AN - SCOPUS:34249815211
SN - 0891-3668
VL - 26
SP - 519
EP - 526
JO - Pediatric Infectious Disease Journal
JF - Pediatric Infectious Disease Journal
IS - 6
ER -